Lanean...
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients’ quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab),...
Gorde:
| Argitaratua izan da: | Psoriasis (Auckl) |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6239126/ https://ncbi.nlm.nih.gov/pubmed/30519540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S165943 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|